Nivalis Therapeutics, Inc. (NASDAQ:NVLS) will report its next earnings on Feb 27 – Mar 3 (Est.). The company reported the earnings of $-0.48/Share in the last quarter where the estimated EPS by analysts was $-0.59/share. The difference between the expected and actual EPS was $0.11/share, which represents an Earnings surprise of 18.6%.
Many analysts are providing their Estimated Earnings analysis for Nivalis Therapeutics, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.56/share. These analysts have also projected a Low Estimate of $-0.62/share and a High Estimate of $-0.51/share.
Some buy side analysts are also providing their Analysis on Nivalis Therapeutics, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 4 Analysts reported that the Price Target for Nivalis Therapeutics, Inc. might touch $30 high while the Average Price Target and Low price Target is $23.75 and $16 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Nivalis Therapeutics, Inc. got Downgrade on 29-Nov-16 where investment firm Stifel Downgrade the stock from Buy to Hold.
Nivalis Therapeutics, Inc. closed its last trading session at $6.25 with the loss of -58.88%. The Market Capitalization of the company stands at 39.94 Million. The Company has 52-week high of $9.46 and 52-week low of $2.5. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -56.96% where SMA50 and SMA200 are -63.15% and -52.65% respectively. The Company Touched its 52-Week High on Dec 22, 2015 and 52-Week Low on Mar 29, 2016.
The Relative Volume of the company is 65.11 and Average Volume (3 months) is 74.74 million. Nivalis Therapeutics, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -39%. The Return on Equity (ROE) value stands at -41.7%. While it’s Return on Investment (ROI) value is 0%.
While looking at the Stock’s Performance, Nivalis Therapeutics, Inc. currently shows a Weekly Performance of -59.72%, where Monthly Performance is -56.59%, Quarterly performance is -59.27%, 6 Months performance is -50% and yearly performance percentage is -69.04%. Year to Date performance value (YTD perf) value is -66.8%. The Stock currently has a Weekly Volatility of 8.23% and Monthly Volatility of 7.46%.